ClinicalTrials.gg
CompletedNCT02183311Updated Jul 8, 2014

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

A Phase 1 interventional study of BI 1356 BS - single rising dose and BI 1356 BS - multiple rising dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

Study to examine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS administered to healthy male volunteers at single rising oral doses (1 mg, 2.5 mg, 5 mg, and 10 mg) and at multiple rising oral doses (2.5 mg, 5 mg, and 10 mg once daily for 12 days)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be healthy male volunteers who meet the criteria below: Persons without clinically remarkable findings or clinically evident complications based on their concurrent illness, past medical history, physical examination, vital signs (blood pressure (BP), pulse rate (PR), and body temperature), 12-lead (ECG), and laboratory test results
  • Persons who are 20 or older and 35 or younger
  • Persons with a 17.6 kg/m2 or more and 29.9 kg/m2 or less
  • Persons who are willing to participate in this trial before study initiation and who give their written consent in accordance with GCP (Good Clinical Practice, MHW Ordinance No. 28 dated March 27, 1997)

Exclusion criteria

Exclusion Criteria:

  • Persons who deviate from the norm and who show clinical findings (BP, PR, and ) on consultation
  • Persons with any complications
  • Persons with gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immune, or hormonal disorders
  • Persons with central nervous system disorders (e.g., epilepsy), mental disorders, or neurological disorders
  • Persons with a history of significant orthostatic hypotension, syncopal attacks, or blackouts
  • Persons with chronic infection or severe acute infection
  • Persons with a history of severe allergy/ including allergies to drugs and inactive ingredients
  • Persons who will have received a drug with a long half-life (more than 24 hours) within the month before treatment in this trial, within a period 10 times longer than the half-life of each drug, or during the study
  • Persons who will have received a drug that may theoretically affect the study results based on the information obtained at the time of preparation of the protocol within the 10 days before treatment or during the study
  • Persons who will have participated in another trial of an drug within the 4 months before treatment or during the study
  • Smokers (who smoke more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Persons who cannot abstain from smoking throughout the study
  • Persons who undoubtedly abuse alcohol
  • Persons who abuse drugs
  • Persons who donate blood of 100 mL or more within the 4 weeks before treatment
  • Persons who perform rigorous exercise (within the week before treatment or during the study)
  • Persons with any laboratory test result outside the reference range and for whom the result is considered a clinically relevant change
  • Persons who cannot obey the dieting rules of the trial site
  • Persons with any ECG value outside the reference range and who are of clinical importance. Examples include, but are not limited to, QRS interval>120 ms
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
56 participants (actual)

Study arms

  • Experimental
    BI 1356 BS - single rising dose

    Drug: BI 1356 BS - single rising dose

  • Experimental
    BI 1356 BS - multiple rising dose

    Drug: BI 1356 BS - multiple rising dose

  • Active comparator
    Placebo

    Drug: Placebo

06

What researchers measure

Primary outcomes

  1. Number of patients with abnormal findings in physical examination

    Time frame: Screening, up to 28 days

  2. Number of patients with clinically significant changes in Vital signs (blood pressure [BP], pulse rate [PR])

    Time frame: Screening, up to 28 days

  3. Number of patients with abnormal findings in 12-lead electrocardiogram (ECG)

    Time frame: Screening, up to 28 days

  4. Number of patients with abnormal changes in laboratory parameters

    Time frame: Screening, up to 28 days

  5. Number of patients with adverse events

    Time frame: up to 49 days

Secondary outcomes

  1. Cmax (maximum measured concentration of the analyte in plasma)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  2. tmax (time from dosing to maximum measured concentration)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  3. AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  4. %AUCtz-∞ (the percentage of the AUCtz-∞ that is obtained by extrapolation)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  5. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable analyte plasma concentration)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  6. AUCt1-t2 (area under the concentration-time curve of the analyte in plasma over the time interval from the time point t1 to the time point t2)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  7. λz (terminal rate constant in plasma)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  8. t1/2 (terminal half-life of the analyte in plasma)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  9. MRTpo (mean residence time of the analyte in the body)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  10. CL/F (apparent clearance of the analyte in plasma after extravascular administration)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  11. Vz/F (apparent volume of distribution during the terminal phase λz following extravascular administration)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  12. Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to the time point t2)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  13. fet1-t2 (fraction of analyte eliminated in urine from the time point t1 to the time point t2)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  14. CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  15. CLR,0-24,1 (renal clearance of the analyte from 0 until 24 hours after administration of the first dose)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  16. Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  17. Cavg (average concentration of the analyte in plasma at steady state)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  18. Cpre (predose concentration of the analyte in plasma)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  19. RA,Cmax based on Cmax

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  20. RA,AUC based on AUCτ

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  21. Emin (minimum Dipeptidyl-Peptidase IV (DPP-IV) activity

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  22. tmin (time to reach minimum DPP-IV activity)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

  23. E24 (DPP-IV activity 24 hours after administration of single dose administration and the first dose of multiple dose administration)

    Time frame: up to 192 h (single dose), up to 456 h (multiple dose)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006 and a primary completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Jun 2006
Primary completionActual
Oct 2006
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183311
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jun 2006
Primary completion
Oct 2006
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion